Education
About Us
Working with TipRanks
Follow Us
Zelira Therapeutics (ZLDAF)
OTHER OTC:ZLDAF
Total Valuation
Zelira Therapeutics has a market cap or net worth of $2.97M. The enterprise value is $7.48M.
Market Cap$2.97M
Enterprise Value$7.48M
Share Statistics
Zelira Therapeutics has 11,897,155 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding11,897,155
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Zelira Therapeutics’s return on equity (ROE) is 0.81 and return on invested capital (ROIC) is 128.84%.
Return on Equity (ROE)0.81
Return on Assets (ROA)-2.79
Return on Invested Capital (ROIC)128.84%
Return on Capital Employed (ROCE)0.92
Revenue Per Employee82.00
Profits Per Employee-453.48K
Employee Count8
Asset Turnover<0.01
Inventory Turnover1.68
Valuation Ratios
The current PE Ratio of Zelira Therapeutics is ―. Zelira Therapeutics’s PEG ratio is 0.02.
PE Ratio―
PS Ratio7702.11
PB Ratio-1.13
Price to Fair Value-1.13
Price to FCF-1.03
Price to Operating Cash Flow-0.95
PEG Ratio0.02
Income Statement
In the last 12 months, Zelira Therapeutics had revenue of 656.00 and earned -3.63M in profits. Earnings per share was -0.32.
Revenue656.00
Gross Profit-802.95K
Operating Income-3.95M
Pretax Income-3.85M
Net Income-3.63M
EBITDA-4.17M
Earnings Per Share (EPS)-0.32
Cash Flow
In the last 12 months, operating cash flow was -4.91M and capital expenditures -5.00, giving a free cash flow of -4.91M billion.
Operating Cash Flow-4.91M
Free Cash Flow-4.91M
Free Cash Flow per Share-0.41
Dividends & Yields
Zelira Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.41
52-Week Price Change-56.25%
50-Day Moving Average0.26
200-Day Moving Average0.29
Relative Strength Index (RSI)21.30
Average Volume (3m)108.00
Important Dates
Zelira Therapeutics upcoming earnings date is Feb 26, 2026, TBA (Confirmed).
Last Earnings DateAug 29, 2025
Next Earnings DateFeb 26, 2026
Ex-Dividend Date―
Financial Position
Zelira Therapeutics as a current ratio of 0.11, with Debt / Equity ratio of -48.01%
Current Ratio0.11
Quick Ratio0.02
Debt to Market Cap0.39
Net Debt to EBITDA-0.51
Interest Coverage Ratio-9.71
Taxes
In the past 12 months, Zelira Therapeutics has paid -1.15M in taxes.
Income Tax-1.15M
Effective Tax Rate0.30
Enterprise Valuation
Zelira Therapeutics EV to EBITDA ratio is -1.72, with an EV/FCF ratio of -1.46.
EV to Sales10.96K
EV to EBITDA-1.72
EV to Free Cash Flow-1.46
EV to Operating Cash Flow-1.46
Balance Sheet
Zelira Therapeutics has $5.66K in cash and marketable securities with $2.14M in debt, giving a net cash position of -$2.14M billion.
Cash & Marketable Securities$5.66K
Total Debt$2.14M
Net Cash-$2.14M
Net Cash Per Share-$0.18
Tangible Book Value Per Share-$0.42
Margins
Gross margin is -122587.02%, with operating margin of -602467.84%, and net profit margin of -553029.27%.
Gross Margin-122587.02%
Operating Margin-602467.84%
Pretax Margin-586840.24%
Net Profit Margin-553029.27%
EBITDA Margin-636296.65%
EBIT Margin-658713.11%
Analyst Forecast
The average price target for Zelira Therapeutics is $0.32, which is 11.43% higher than the current price. The consensus rating is Moderate Sell
Price Target$0.32
Price Target Upside52.38% Upside
Analyst ConsensusModerate Sell
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―